SBI : ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED MARCH 31, 2021

SBI HOLDINGS, INC.

(Incorporated in Japan with limited liability)

ANNUAL RESULTS ANNOUNCEMENT

FOR THE YEAR ENDED MARCH 31, 2021

The board of directors (the "Directors") of SBI HOLDINGS, INC. (the "Company") is pleased to announce the consolidated results of the Company and its subsidiaries (collectively the "Group") for the year ended March 31, 2021.

(Amounts are rounded to the nearest million Japanese yen)

1. Consolidated Financial Results

1. Consolidated Operating Results

(Percentages represent year-on-year changes)

				Profit before income				Profit attributable to
	Revenue		Profit for the year	owners of the
		tax expense
							Company
	Millions of	%	Millions of	%	Millions of	%	Millions of	%
	yen	yen		yen	yen
Fiscal year ended	541,145	47.0		140,380	113.3		97,512	116.7	81,098	116.3
March 31, 2021
Fiscal year ended	368,055	4.7		65,819	(20.7)		45,000	(33.1)	37,487	(28.7)
March 31, 2020
	Total comprehensive	Basic earnings per share	Diluted earnings per share
	attributable to owners of	attributable to owners of
	income
			the Company			the Company
	Millions of	%			Yen		Yen
	yen
Fiscal year ended	122,187	479.3				339.78		296.92
March 31, 2021
Fiscal year ended	21,091	(66.7)			163.18		147.44
March 31, 2020
	Ratio of profit to equity	Ratio of profit before	Ratio of operating income
	attributable to owners of the	income tax expense
	to operating revenue
	Company			to total assets
				%			%		%
Fiscal year ended				16.0			2.2			25.9
March 31, 2021
Fiscal year ended				8.3			1.2			17.9
March 31, 2020
(Note) Share of results of associates	Fiscal year ended March 31, 2021: 9,458 million yen
			Fiscal year ended March 31, 2020: 6,527 million yen

1

(2) Consolidated Financial Position

				Ratio of equity	Equity per share
			Equity attributable	attributable to
			attributable to
	Total assets	Total equity	to owners of	owners of
	owners of the
			the Company	the Company to
			Company
				total assets
	Millions of yen	Millions of yen	Millions of yen	%	Yen
March 31, 2021	7,208,572	717,095	562,116	7.8	2,297.87
March 31, 2020	5,513,227	593,699	451,476	8.2	1,955.91

(3) Consolidated Cash Flows

				Cash and cash
	Operating activities	Investing activities	Financing activities	equivalents at the
				end of the year
	Millions of yen	Millions of yen	Millions of yen	Millions of yen
Fiscal year ended	(178,403)	(82,071)	210,822	802,702
March 31, 2021
Fiscal year ended	26,849	(70,887)	181,626	843,755
March 31, 2020

2. Dividends

		Dividend per share				Ratio of
					dividend to
						Total	Payout ratio	equity
						dividend	attributable
	End of	End of	End of			(cons.)
(Declared date)	Year-end	Full year	(annual)	to owners of
1st Q	2nd Q	3rd Q
					the Company
								(cons.)
	Yen	Yen	Yen	Yen	Yen	Millions	%	%
	of yen
Fiscal year ended	－	20.00	－	80.00	100.00	23,077	61.3	5.1
March 31, 2020
Fiscal year ended	－	20.00	－	100.00	120.00	29,324	35.3	5.6
March 31, 2021
Fiscal Year ending
March 31, 2022	－	－	－	－	－		－
(forecast) (Note)

(Note) Fiscal year ending March 31, 2022 forecast is to be determined.

3. Total number of shares outstanding (Common stock)

(1)	Number of shares outstanding (including	:	March 31, 2021	:	244,639,390shares
	treasury stock)		March 31, 2020	:	236,556,393shares
(2)	Number of treasury stock	:	March 31, 2021	:	15,084shares
			March 31, 2020	:	5,730,038shares
(3)	Average number of shares outstanding	:	Year ended March 31, 2021	:	238,676,048shares
			Year ended March 31, 2020	:	229,724,077shares

The Group prepared the consolidated financial statements in accordance with IFRSs.

2

(Reference Information)

Non-consolidated Financial Results

(1) Non-consolidated Operating Results

(Percentages represent year-on-year changes)

	Net sales	Operating income	Ordinary income	Net income
	Millions of	%	Millions of	%	Millions of	%	Millions of	%
	yen	yen	yen	yen
Fiscal year ended	88,901	178.4	70,786	446.7	69,573	632.5	23,499	114.9
March 31, 2021
Fiscal year ended	31,937	16.9	12,947	62.9	9,498	365.6	10,938	100.4
March 31, 2020
	Net income	Diluted net income
	per share	per share
		Yen		Yen
Fiscal year ended		98.46		84.11
March 31, 2021
Fiscal year ended		47.61		41.28
March 31, 2020
(2) Non-consolidated Financial Position
	Total assets	Net assets	Ratio of shareholder's	Net assets
	equity to total assets	per share
	Millions of yen	Millions of yen		%		Yen
March 31, 2021	1,085,970		392,485		36.0		1,598.81
March 31, 2020		894,301		351,074		39.1		1,515.98
(Note) Shareholders' equity		Fiscal year ended March 31, 2021: 391,107 million yen
			Fiscal year ended March 31, 2020: 349,927 million yen

The non-consolidated financial results were prepared in accordance with JGAAP.

This financial summary is not subject to audit.

3

1. BUSINESS RESULTS

1. Overview of Business Results for the Fiscal Year
   The Group's consolidated results of operations for the fiscal year ended March 31, 2021 were as follow. Revenue increased 47.0% year-on-year to ¥541,145 million, profit before income tax expense increased 113.3% to ¥140,380 million, and profit attributable to owners of the Company increased 116.3% to ¥81,098 million.
   The results of operations for each reporting segment of the Group for the fiscal year ended March 31, 2021 were as follow.
   The Group changed the reporting segment name "Biotechnology-related Business" to "Biotechnology, Healthcare & Medical Informatics Business" from the third quarter ended December 31, 2020.
   SBI Leasing Services Co., Ltd., which was included in the Financial Services Business until the previous reporting period, and SBI Crypto Investment Co., Ltd., which was included in the Others until the previous reporting period, are now included in the Asset Management Business beginning with this fiscal year. SBI CapitalBase Co., Ltd., which was included in the Others until the previous reporting period and changed its company name to SBI Equity Crowd Co., Ltd. on July 1, 2020, is now included in the Financial Services Business beginning with this fiscal year. Consequently, segment information for the year ended March 31, 2020, is restated in accordance with the new basis of segmentation.

		Revenue		Profit before income tax expense
	Fiscal year			Fiscal year
	ended	Fiscal year ended	ended	Fiscal year ended
	March 31,	March 31,
	2020	March 31, 2021	2020	March 31, 2021
	Millions of	Millions of	%	Millions of	Millions of	%
	Yen	Yen	Yen	Yen
Financial Services Business	236,751	311,724	31.7	51,275	85,755	67.2
Asset Management Business	126,585	208,332	64.6	37,230	84,853	127.9
Biotechnology, Healthcare &	3,920	5,627	43.5	(11,431)	(8,630)	－
Medical Informatics Business
Total	367,256	525,683	43.1	77,074	161,978	110.2
Others	5,226	21,740	316.0	(1,733)	(10,595)	－
Elimination or Corporate	(4,427)	(6,278)	－	(9,522)	(11,003)	－
Consolidated Total	368,055	541,145	47.0	65,819	140,380	113.3

(% represents year-on-year changes)

(Financial Services Business)

The Financial Services Business consists of a wide range of finance-related business, including securities brokerage business, banking services business and life, property and casualty insurance business.

The results of operations of the Financial Services Business for the fiscal year ended March 31, 2021 were as follows. Revenue increased 31.7% year-on-year to ¥311,724 million, and profit before income tax expense increased 67.2% to ¥85,755 million. This was mainly due to higher sales and profits in the securities business as a result of favorable stock market conditions compared to the previous fiscal year.

4

(Asset Management Business)

The Asset Management Business primarily consists of fund management and investment in Internet technology, fintech, blockchain, finance, and biotechnology-related venture companies in Japan and overseas, financial services business overseas, and asset management services business which provides financial products information.

The results of operations of the Asset Management Business for the fiscal year ended March 31, 2021 were as follows. Revenue increased 64.6% year-on-year to ¥208,332 million, and profit before income tax expense increased 127.9% year-on-year to ¥84,853 million. This was mainly due to an increase in "Income arising from financial assets measured at FVTPL" recognized on investments in companies.

(Biotechnology, Healthcare & Medical Informatics Business)

The Biotechnology, Healthcare & Medical Informatics Business represents development and distribution of pharmaceutical products, health foods, and cosmetics with 5-aminolevulinic acid (ALA*), a kind of amino acid which exists in vivo, research and development of antibody drugs and nucleic acid medicine in the field of cancer and immunology, the digitization of medical and health information, providing solutions and services that promote and the use of medical big data, and medical finance.

The results of operations of the Biotechnology, Healthcare & Medical Informatics Business for the fiscal year ended March 31, 2021 were as follows. Revenue increased 43.5% year-on-year to ¥5,627 million, and loss before income tax expense amounted to ¥8,630 million for the fiscal year ended March 31, 2021 (¥11,431 million of loss before income tax expense for the fiscal year ended March 31, 2020).

1. • Five-aminolevulinicacid (ALA) is an amino acid generated by mitochondria in the human body and an important substance used to produce heme or cytochrome, proteins to generate energy. The production of ALA in the human body decreases with age. ALA is included in food products, including slops of distilled spirits, red wine, and Asian ginseng. ALA is also known as a chloroplastic substance in plants.
2. Overview of Financial Conditions for the Fiscal Year
   As at March 31, 2021, total assets amounted to ¥7,208,572 million and increased by ¥1,695,345 million from total assets of ¥5,513,227 million as at March 31, 2020. The Group's equity increased by ¥123,396 million to ¥717,095 million from the fiscal year ended March 31, 2020. As at March 31, 2021, the Group's cash and cash equivalents amounted to ¥802,702 million and decreased by ¥41,053 million from that of ¥843,755 million as at March 31, 2020. The changes of cash flows for each activity and the reasons for changes are as follows:
   (Operating Cash Flows)
   Cash flows from operating activities amounted to ¥178,403 million in net cash outflows (¥26,849 million in net cash inflows for the year ended March 31, 2020). The net cash outflows were primarily due to a ¥246,508 million cash outflow from an increase in trade and other accounts receivables, a ¥221,904 million cash outflow from an increase in assets/liabilities related to securities business and a ¥131,448 million cash outflow from an increase in operational investment securities, despite a ¥220,081 million cash inflow from an increase in customer deposits in the banking business and a ¥140,380 million cash inflow from a profit before income tax expense.
   (Investing Cash Flows)
   Cash flows from investing activities amounted to ¥82,071 million in net cash outflows (¥70,887 million in net cash outflows for the year ended March 31, 2020). The net cash outflows were primarily due to a ¥77,392 million cash outflow from purchases of investment securities and a ¥70,172 million cash outflow from payments of loans receivable, despite a ¥49,860 million cash inflow from collection of loans receivable.

5

(Financing Cash Flows)

Cash flows from financing activities amounted to ¥210,822 million in net cash inflows (¥181,626 million in net cash inflows for the year ended March 31, 2020). The net cash inflows were primarily due to a ¥228,124 million cash inflow from proceeds from issuance of bonds payable and a ¥69,808 million cash inflow from an increase in short term loans payable, despite a ¥112,576 million cash outflow from redemption of bonds payable.

2. THE BASIC CONCEPT REGARDING SELECTION OF ACCOUNTING STANDARDS

The Group applied IFRS from the fiscal year ended March 31, 2013 in order to improve the international comparability of financial information in the capital markets.

6

3. CONSOLIDATED FINANCIAL STATEMENTS AND NOTES

1. Consolidated Statement of Financial Position

	As at March 31,		As at March 31,
	2020	2021
	Millions of Yen		Millions of Yen
Assets
Cash and cash equivalents	843,755	802,702
Trade and other accounts receivable	822,131	1,183,896
Assets related to securities business
Cash segregated as deposits	1,726,040	2,292,743
Margin transaction assets	495,997	972,573
Other assets related to securities business	576,501	631,305
Total assets related to securities business	2,798,538	3,896,621
Other financial assets	40,994	58,715
Operational investment securities	394,923	528,154
Other investment securities	180,444	209,545
Investments accounted for using the equity method	63,657	103,807
Property and equipment	51,857	64,290
Intangible assets	190,278	225,607
Other assets	116,765	123,071
Deferred tax assets	9,885	12,164
Total assets	5,513,227	7,208,572
Liabilities
Bonds and loans payable	1,149,050	1,394,137
Trade and other accounts payable	76,977	189,729
Liabilities related to securities business
Margin transaction liabilities	150,699	269,152
Loans payable secured by securities	351,701	602,921
Deposits from customers	959,773	1,277,808
Guarantee deposits received	819,838	961,651
Other liabilities related to securities business	392,347	410,270
Total liabilities related to securities business	2,674,358	3,521,802
Customer deposits for banking business	734,221	1,042,132
Insurance contract liabilities	141,898	150,123
Income tax payable	11,373	20,125
Other financial liabilities	23,083	30,333
Other liabilities	88,925	107,301
Deferred tax liabilities	19,643	35,795
Total liabilities	4,919,528	6,491,477
Equity
Capital stock	92,018	98,711
Capital surplus	139,993	147,753
Treasury stock	(13,874)	(40)
Other components of equity	(6,385)	18,197
Retained earnings	239,724	297,495
Equity attributable to owners of the Company	451,476	562,116
Non-controlling interests	142,223	154,979
Total equity	593,699	717,095
Total liabilities and equity	5,513,227	7,208,572

7

1. Consolidated Statements of Income and Comprehensive Income Consolidated Statement of Income

	Fiscal year ended	Fiscal year ended
	March 31, 2020	March 31, 2021
	Millions of Yen	Millions of Yen
Revenue (Interest income of ¥118,779 million and
¥143,364 million included for the year ended March 31,	368,055	541,145
2020 and 2021, respectively)
Expense
Financial cost associated with financial income	(25,186)	(26,773)
Provision for credit losses	(31,567)	(41,147)
Operating cost	(110,696)	(142,519)
Selling, general and administrative expenses	(132,226)	(163,326)
Other financial cost	(5,140)	(5,803)
Other expenses	(3,948)	(30,655)
Total expense	(308,763)	(410,223)
Share of the profit of associates and joint ventures	6,527	9,458
accounted for using the equity method
Profit before income tax expense	65,819	140,380
Income tax expense	(20,819)	(42,868)
Profit for the year	45,000	97,512
Profit for the year attributable to
Owners of the Company	37,487	81,098
Non-controlling interests	7,513	16,414
Profit for the year	45,000	97,512
Earnings per share attributable to owners of the
Company
Basic (Yen)	163.18	339.78
Diluted (Yen)	147.44	296.92

8

Consolidated Statement of Comprehensive Income

	Fiscal year ended	Fiscal year ended
	March 31, 2020	March 31, 2021
	Millions of Yen	Millions of Yen
Profit for the year	45,000	97,512
Other comprehensive income
Items that will not be reclassified subsequently to
profit or loss
Equity instruments measured at FVTOCI	(639)	(18)
Share of other comprehensive income of
associates and joint ventures accounted for	(384)	109
using the equity method
	(1,023)	91
Items that may be reclassified subsequently to
profit or loss
Debt instruments measured at FVTOCI	349	(168)
Currency translation differences	(19,807)	23,871
Share of other comprehensive income of
associates and joint ventures accounted for	(3,428)	881
using the equity method
	(22,886)	24,584
Other comprehensive income, net of tax	(23,909)	24,675
Total comprehensive income	21,091	122,187
Total comprehensive income attributable to
Owners of the Company	13,519	105,680
Non-controlling interests	7,572	16,507
Total comprehensive income	21,091	122,187

9

(3) Consolidated Statement of Changes in Equity

Attributable to owners of the Company

																						Non-controlling			Total
												Other
																					interests			equity
	Capital			Capital				Treasury				components			Retained
	stock			surplus				stock				of equity			earnings			Total
	Millions			Millions				Millions				Millions			Millions			Millions				Millions			Millions
	of Yen			of Yen				of Yen				of Yen			of Yen			of Yen				of Yen			of Yen
As at April 1, 2019	92,018	142,094	(20,128)	16,977	225,714	456,675	105,882	562,557
Profit for the year	-	-	-	-	37,487	37,487	7,513	45,000
Other comprehensive	-	-	-	(23,968)	-	(23,968)	59	(23,909)
income
Total comprehensive
-	-	-	(23,968)	37,487	13,519	7,572	21,091
income
Conversion of convertible	-	(1,496)	4,821	-	-	3,325	-	3,325
bonds
Change in scope of	-	-	-	-	-	-	(4,476)	(4,476)
consolidation
Dividends paid	-	-	-	-	(22,871)	(22,871)	(13,701)	(36,572)
Treasury shares	-	-	(16)	-	-	(16)	-	(16)
purchased
Treasury shares sold	-	(514)	1,449	-	-	935	-	935
Share-based payment	-	225	-	-	-	225	583	808
transactions
Changes of interests in
subsidiaries without losing	-	(316)	-	-	-	(316)	46,363	46,047
control
Transfer	-	-	-	606	(606)	-	-	-
As at March 31, 2020
92,018	139,993	(13,874)	(6,385)	239,724	451,476	142,223	593,699
Profit for the year
-	-	-	-	81,098	81,098	16,414	97,512
Other comprehensive	-	-	-	24,582	-	24,582	93	24,675
income
Total comprehensive
-	-	-	24,582	81,098	105,680	16,507	122,187
income
Issuance of new shares	2,652	2,271	-	-	-	4,923	-	4,923
Issuance of convertible	-	2,756	-	-	-	2,756	-	2,756
bonds
Conversion of convertible	4,041	(484)	12,805	-	-	16,362	-	16,362
bonds
Change in scope of	-	-	-	-	-	-	(9,788)	(9,788)
consolidation
Dividends paid	-	-	-	-	(23,327)	(23,327)	(15,018)	(38,345)
Treasury shares	-	-	(39)	-	-	(39)	-	(39)
purchased
Treasury shares sold	-	(378)	1,068	-	-	690	-	690
Share-based payment	-	799	-	-	-	799	(5)	794
transactions
Changes of interests in
subsidiaries without	-	2,796	-	-	-	2,796	21,060	23,856
losing control
As at March 31, 2021
98,711	147,753	(40)	18,197	297,495	562,116	154,979	717,095

10

(4) Consolidated Statement of Cash flows

Cash flows from operating activities Profit before income tax expense Depreciation and amortization

Share of profits of associates and joint ventures accounted for using the equity method

Interest and dividend income Interest expense Increase in operational investment securities Increase in trade and other accounts receivables Increase in trade and other accounts payable

Decrease (Increase) in assets/liabilities related to securities business

Increase in customer deposits in the banking business Others Subtotal Interest and dividend income received Interest paid Income taxes paid Net cash generated (used in) from operating activities Cash flows from investing activities Purchases of intangible assets Purchases of investment securities

Proceeds from sales or redemption of investment securities

Acquisition of subsidiaries, net of cash and cash equivalents acquired

Payments of loans receivable Collection of loans receivable Others Net cash used in investing activities

Fiscal year ended	Fiscal year ended
March 31, 2020	March 31, 2021
Millions of Yen	Millions of Yen
65,819	140,380
15,904	24,291
(6,527)	(9,458)
(123,412)	(150,325)
30,318	32,573
(114,172)	(131,448)
(146,427)	(246,508)
5,711	88,237
78,095	(221,904)
139,580	220,081
775	(17,223)
(54,336)	(271,304)
125,116	145,959
(28,214)	(29,281)
(15,717)	(23,777)
26,849	(178,403)
(14,250)	(15,419)
(36,885)	(77,392)
39,404	40,735
(10,077)	(8,026)
(50,303)	(70,172)
24,431	49,860
(23,207)	(1,657)
(70,887)	(82,071)

11

Cash flows from financing activities Increase in short term loans payable Proceeds from long-term loans payable Repayment of long-term loans payable Proceeds from issuance of bonds payable Redemption of bonds payable Proceeds from issuance of shares Proceeds from stock issuance to non-controlling interests

Contributions from non-controlling interests in consolidated investment funds

Cash dividends paid Cash dividends paid to non-controlling interests

Distributions to non-controlling interests in consolidated investment funds

Purchase of treasury stock

Proceeds from sale of interests in subsidiaries to non- controlling interests

Payments for purchase of interests in subsidiaries from non-controlling interests

Others Net cash generated from financing activities Net increase (decrease) in cash and cash equivalents Cash and cash equivalents at the beginning of the year

Effect of changes in exchange rate on cash and cash equivalents

Cash and cash equivalents at the end of the year

Fiscal year ended	Fiscal year ended
March 31, 2020	March 31, 2021
Millions of Yen	Millions of Yen
26,604	69,808
58,043	54,936
(37,948)	(21,953)
179,889	228,124
(46,626)	(112,576)
-	4,923
5,354	6,356
35,646	15,572
(22,860)	(23,313)
(718)	(763)
(13,008)	(14,243)
(14)	(39)
302	9,223
(50)	(155)
(2,988)	(5,078)
181,626	210,822
137,588	(49,652)
713,974	843,755
(7,807)	8,599
843,755	802,702

12

(5) Notes to Consolidated Financial Statements

1.Segment Information

The Group engages in a wide range of business activities, primarily online financial service businesses and investment activities in Japan and overseas. Based on the similarities or economic characteristics of business or nature of services, "Financial Services Business", "Asset Management Business", and "Biotechnology, Healthcare & Medical Informatics Business", which is anticipated to be a growth industry in the 21st century, are determined as reportable segments.

The reportable segments of the Group represent businesses activities for which separate financial information of the Group's components is available and reviewed regularly by the board of directors for the purpose of allocation of financial resources and performance evaluation.

The following is a description of business activities for the reporting segments.

The Group changed the reporting segment name "Biotechnology-related Business" to "Biotechnology, Healthcare & Medical Informatics Business" from the third quarter ended December 31, 2020.

"Financial Services Business"

The Financial Services Business consists of a wide range of finance-related business, including securities brokerage business, banking services business, and life, property and casualty insurance business.

"Asset Management Business"

The Asset Management Business primarily consists of fund management and investment in Internet technology, fintech, blockchain, finance, and biotechnology-related venture companies in Japan and overseas, financial services business overseas, and asset management services business which provides financial products information.

"Biotechnology, Healthcare & Medical Informatics Business"

The Biotechnology, Healthcare & Medical Informatics Business represents development and distribution of pharmaceutical products, health foods, and cosmetics with 5-aminolevulinic acid (ALA*), a kind of amino acid which exists in vivo, research and development of antibody drugs and nucleic acid medicine in the field of cancer and immunology, the digitization of medical and health information, providing solutions and services that promote and the use of medical big data, and medical finance.

"Others" includes the digital asset-related business, the real estate business, the renewable energy business and other businesses, but they did not meet the quantitative criteria to be defined as reportable segments for the fiscal year ended March 31, 2021.

"Elimination or Corporate" includes profit or loss that is not allocated to certain business segments and the elimination of the inter-company transactions within the Group, at a price based on the actual market price.

13

The following represents segment information of the Group:

SBI Leasing Services Co., Ltd., which was included in the Financial Services Business until the previous reporting period, and SBI Crypto Investment Co., Ltd., which was included in the Others until the previous reporting period, are now included in the Asset Management Business beginning with this fiscal year. SBI CapitalBase Co., Ltd., which was included in the Others until the previous reporting period and changed its company name to SBI Equity Crowd Co., Ltd. on July 1, 2020, is now included in the Financial Services Business beginning with this fiscal year. Consequently, segment information for the year ended March 31, 2020, is restated in accordance with the new basis of segmentation.

For the year ended March 31, 2020
			Biotechnology,
			Healthcare &
	Financial	Asset	Medical
	Services	Management	Informatics				Consolidated
	Business	Business	Business	Total	Others	Elimination	Total
	Millions of	Millions of	Millions of	Millions of	Millions of	Millions of	Millions of
	Yen	Yen	Yen	Yen	Yen	Yen	Yen
Revenue	236,751	126,585	3,920	367,256	5,226	(4,427)	368,055
Profit (loss) before	51,275	37,230	(11,431)	77,074	(1,733)	(9,522)	65,819
income tax expense
For the year ended March 31, 2021
			Biotechnology,
			Healthcare &
	Financial	Asset	Medical
	Services	Management	Informatics				Consolidated
	Business	Business	Business	Total	Others	Elimination	Total
	Millions of	Millions of	Millions of	Millions of	Millions of	Millions of	Millions of
	Yen	Yen	Yen	Yen	Yen	Yen	Yen
Revenue	311,724	208,332	5,627	525,683	21,740	(6,278)	541,145
Profit (loss) before	85,755	84,853	(8,630)	161,978	(10,595)	(11,003)	140,380
income tax expense

14

2. Revenue

	Fiscal year ended	Fiscal year ended
	March 31, 2020	March 31, 2021
	Millions of yen	Millions of yen
Financial income
Interest income
Income arising from financial assets measured at	117,992	142,628
amortized cost (Note 1)
Income arising from debt instruments measured at	787	736
FVTOCI (Note 2)
Income arising from financial assets measured at FVTPL	48,723	133,532
Others	184	576
Total financial income	167,686	277,472
Revenue arising on insurance contracts	87,517	96,301
Revenue from contracts with customers
Revenue from rendering of services	83,187	105,431
Revenue from sales of goods	6,014	14,898
Others	23,651	47,043
Total revenue	368,055	541,145

(Note 1) Interest income arising from loans in the banking and securities businesses.

(Note 2) Interest income arising from bonds in the insurance business.

3. Earnings per Share

The basic and diluted earnings per share attributable to owners of the Company are calculated based on the following information.

Earnings

Profit attributable to owners of the Company Dilutive effect: Convertible bonds

Profit attributable to owners of the Company after dilutive effect

Shares

Basic weighted average number of ordinary shares

Dilutive effect: Stock options

Dilutive effect: Convertible bonds

Weighted average number of ordinary shares after the dilutive effect

Earnings per share attributable to owners of the Company

Basic

Diluted

Fiscal year ended		Fiscal year ended
March 31, 2020		March 31, 2021
Millions of yen		Millions of yen
37,487	81,098
374	664
37,861	81,762
Shares		Shares
229,724,077	238,676,048
1,969,058	2,244,040
25,094,962	34,445,617
256,788,097	275,365,705
Yen		Yen
163.18	339.78
147.44	296.92

4. Events after the Reporting Period

There was no significant event after the reporting period.

15